A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
Abstract Breast cancer (BC), specifically HER2‐positives subtype, has a poor prognosis. Nevertheless, the development of anti‐HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti‐HER2 therapy is crucial. The advent of deep lear...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | iMetaOmics |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imo2.19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575924792459264 |
|---|---|
| author | Xinpei Deng Yixuan Yan Zekai Zhan Jindong Xie Hailin Tang Yutian Zou Jian Tu Peng Liu |
| author_facet | Xinpei Deng Yixuan Yan Zekai Zhan Jindong Xie Hailin Tang Yutian Zou Jian Tu Peng Liu |
| author_sort | Xinpei Deng |
| collection | DOAJ |
| description | Abstract Breast cancer (BC), specifically HER2‐positives subtype, has a poor prognosis. Nevertheless, the development of anti‐HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti‐HER2 therapy is crucial. The advent of deep learning has propelled the artificial intelligence (AI) revolution, leading to an increased applicability of AI in predictive models. In the field of medicine, AI is an emerging modality that is gaining momentum for facilitating cancer diagnosis and treatment, particularly in the effective management of breast cancer. This study aims to provide a comprehensive review of current diagnostic and predictive models that utilize data obtained from histopathological slides, radiomics, and HER2 binding sites. Advancements and practical applications of these models were also evaluated. Additionally, we examined existing obstacles that AI encounters for anti‐HER2 therapy. We also proposed future directions for integrating AI in assessing and managing anti‐HER2 therapy. The findings of this study offer valuable insights into the evaluation of AI‐based anti‐HER2 therapy, emphasizing key concepts and obstacles that, if addressed, could facilitate the integration of AI‐assisted anti‐HER2 therapy. The integration of AI has the potential to enhance the precision and customization of screening and treatment protocols for HER2+ breast cancer. |
| format | Article |
| id | doaj-art-8c5e0d4929524ccb8160ec92b2a4589c |
| institution | Kabale University |
| issn | 2996-9506 2996-9514 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | iMetaOmics |
| spelling | doaj-art-8c5e0d4929524ccb8160ec92b2a4589c2025-01-31T16:15:20ZengWileyiMetaOmics2996-95062996-95142024-09-0111n/an/a10.1002/imo2.19A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer managementXinpei Deng0Yixuan Yan1Zekai Zhan2Jindong Xie3Hailin Tang4Yutian Zou5Jian Tu6Peng Liu7State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou ChinaGuanghua School of Stomatology Sun Yat‐sen University Guangzhou ChinaSchool of Medicine Sun Yat‐sen University Shenzhen ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou ChinaPharmacy School of Guilin Medical University Guilin Guangxi ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou ChinaAbstract Breast cancer (BC), specifically HER2‐positives subtype, has a poor prognosis. Nevertheless, the development of anti‐HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti‐HER2 therapy is crucial. The advent of deep learning has propelled the artificial intelligence (AI) revolution, leading to an increased applicability of AI in predictive models. In the field of medicine, AI is an emerging modality that is gaining momentum for facilitating cancer diagnosis and treatment, particularly in the effective management of breast cancer. This study aims to provide a comprehensive review of current diagnostic and predictive models that utilize data obtained from histopathological slides, radiomics, and HER2 binding sites. Advancements and practical applications of these models were also evaluated. Additionally, we examined existing obstacles that AI encounters for anti‐HER2 therapy. We also proposed future directions for integrating AI in assessing and managing anti‐HER2 therapy. The findings of this study offer valuable insights into the evaluation of AI‐based anti‐HER2 therapy, emphasizing key concepts and obstacles that, if addressed, could facilitate the integration of AI‐assisted anti‐HER2 therapy. The integration of AI has the potential to enhance the precision and customization of screening and treatment protocols for HER2+ breast cancer.https://doi.org/10.1002/imo2.19anti‐HER2 therapyartificial intelligencebreast cancerimage recognitionradiogenomics |
| spellingShingle | Xinpei Deng Yixuan Yan Zekai Zhan Jindong Xie Hailin Tang Yutian Zou Jian Tu Peng Liu A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management iMetaOmics anti‐HER2 therapy artificial intelligence breast cancer image recognition radiogenomics |
| title | A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management |
| title_full | A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management |
| title_fullStr | A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management |
| title_full_unstemmed | A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management |
| title_short | A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management |
| title_sort | glimpse into the future integrating artificial intelligence for precision her2 positive breast cancer management |
| topic | anti‐HER2 therapy artificial intelligence breast cancer image recognition radiogenomics |
| url | https://doi.org/10.1002/imo2.19 |
| work_keys_str_mv | AT xinpeideng aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT yixuanyan aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT zekaizhan aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT jindongxie aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT hailintang aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT yutianzou aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT jiantu aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT pengliu aglimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT xinpeideng glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT yixuanyan glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT zekaizhan glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT jindongxie glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT hailintang glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT yutianzou glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT jiantu glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement AT pengliu glimpseintothefutureintegratingartificialintelligenceforprecisionher2positivebreastcancermanagement |